Camostat-d6 is intended for use as an internal standard for the quantification of camostat by GC- or LC-MS. Camostat (50 µM) inhibits entry of vesicular stomatitis virus (VSV) particles pseudotyped with severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 surface glycoprotein in Calu-3 cells and primary human lung epithelial cells.1 It reduces the number of SARS-CoV-2 genomic equivalents, a marker of infection, in Calu-3 cells. Camostat inhibits sodium channel function in human airway epithelial cells (IC50 = 50 nM) and enhances mucociliary clearance in sheep.2 Dietary administration of camostat (1 mg/kg) inhibits the production of TNF-α and chemokine (C-C motif) ligand 2 (CCL2) by monocytes, as well as proliferation of pancreatic stellate cells in a rat model of pancreatic fibrosis.3
1.Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitorCell181(2)271-280(2020) 2.Maianti, J.P., McFedries, A., Foda, Z.H., et al.Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormonesNature511(7507)94-98(2014) 3.Gibo, J., Ito, T., Kawabe, K., et al.Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activityLab Invest.85(1)75-89(2005)